{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01624701",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2009/925/B"
      },
      "Organization": {
        "OrgFullName": "Singapore General Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells",
      "OfficialTitle": "Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells: A Pilot Trial in Collaboration With the Massachusetts Institute of Technology"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2015",
      "OverallStatus": "Terminated",
      "WhyStopped": "Funding expired",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2012"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 2015",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 2016",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "March 20, 2012",
      "StudyFirstSubmitQCDate": "June 20, 2012",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 21, 2012",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 26, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 30, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Singapore General Hospital",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Whitehead Institute for Biomedical Research",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Blood Services Group, Health Sciences Authority of Singapore",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a pilot clinical trial to assess the feasibility and efficacy of expanding umbilical cord blood derived blood stem cells for transplantation using a combination of chemical factors and stromal co-culture. Bone marrow (BM) mesenchymal stromal cells (MSC) will be obtained from a separate bone marrow donor. One cord blood unit will be expanded by this method while another cord blood unit will be infused without manipulation. The expanded cord blood unit will help boost the initial recovery of blood counts after transplantation, though it is expected that the unexpanded cord blood unit will provide the cells which will lead to long term engraftment of blood stem cells. A third cord blood unit will be identified for standby should the cord blood unit expansion fail.",
      "DetailedDescription": "Clinical transplantation of two cord blood units: one ex vivo expanded while another unmanipulated unit to function as a back-up.\n\nTen patients will be selected from those for whom:\n\nAllogeneic haematopoietic stem cell transplant is indicated (see details)\nNo matched sibling or matched unrelated donor is available quickly enough for the transplant (no fully matched donor found within 1 month of initiation of donor search or donor found but not available for donation within 3 months of donor search).\nAt least three unrelated donor cord blood unit can be identified with less than 2 antigens mismatches with the patient but with insufficient cell dose to meet the patient's requirements. If clinical efficacy of this protocol is demonstrated, we will proceed to a multicentre clinical trial with more patients.\nThe investigators will obtain haplo-identical MSC from the bone marrow of sibling/parent/offspring of the patient. Although there will be some MSC co-infused with the cord blood cells, this has been shown to be safe in trials of MSC given for patients with graft versus host disease (GVHD) and human leukocyte antigen (HLA) matching of MSC and recipient has been shown to be not important. bone marrow mesenchymal stroma cells (BM-MSCs) derived from related donor bone marrow with a minimum of 2/6 HLA match have been safe for use in patients.1 If the haplo-identical MSC donor is not available, matched unrelated donor MSC would also be used.\n\nEfficacy will be assessed by the following and compared to published literature as well as historical controls:\n\nNeutrophil and platelet engraftment\nPost transplant 100-day mortality\nOverall and progression-free survival If clinical efficacy of this protocol is demonstrated, the investigators will proceed to a multicentre clinical trial with more patients."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Acute Leukemia",
          "Chronic Leukemia",
          "Myelodysplastic Syndrome",
          "Lymphoma",
          "Myeloma"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Cord blood",
          "unrelated donor",
          "allogeneic",
          "cell dose"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "3",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Expanded",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "'Ex vivo expanded cord blood cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Ex vivo expanded cord blood cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Other",
            "InterventionName": "Ex vivo expanded cord blood cells",
            "InterventionDescription": "Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Expanded"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety",
            "PrimaryOutcomeDescription": "Number of subjects with infusional toxicities (including fever, renal dysfunction within 72 hours of infusion) and potential immunologic competition (absent chimerism of donor cells by 21 days post transplantation).",
            "PrimaryOutcomeTimeFrame": "1 month"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Engraftment",
            "SecondaryOutcomeDescription": "Neutrophil engraftment (ANC>500/ul) in subjects as demonstrated by number of subjects with engraftment <=21 days.",
            "SecondaryOutcomeTimeFrame": "2 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients will be from the Department of Haematology, Singapore General Hospital, who have the diagnoses listed below and who meet the inclusion criteria. They have to be deemed suitable for trial by the respective attending doctor as well as a panel of at least three hematologists. Suitability will be reassessed by the Principal Investigator again\n\nPatients aged 12 years to 60 years.\nPatient has no currently available HLA-A, B, C, DRB1 and DQB1 matched related or unrelated donor.\nPatient must have a hematologic malignancy requiring allogeneic haematopoietic stem cell transplantation as further defined below (from National Marrow Donor Program and American Society of Blood and Marrow Transplantation Guidelines) and as further agreed upon by a panel of at least three hematologists specializing in transplantation.\n\nAcute myelogenous leukemia (AML): High-risk AML including:\n\nAntecedent hematological disease (e.g., myelodysplasia (MDS))\nTreatment-related leukemia\nInduction failure\n1st complete remission (CR1) with poor-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23 etc)\n2nd complete remission (CR2) and beyond\n\nAcute lymphoblastic leukemia (ALL)\n\nCR1 up to age 35\nHigh-risk over age 35 including:\nPoor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22)or 11q23 rearrangements)\nHigh white cell count (> 30,000/mm3) at diagnosis\nCNS or testicular leukemia\nNo CR within 4 weeks of initial treatment\nInduction failure\nCR2 and beyond\n\nMyelodysplastic syndromes (MDS)\n\nIntermediate-1 (INT-1), intermediate-2 (INT-2) or high IPSS score which includes:\n> 5% marrow blasts\nOther than good risk cytogenetics (not 5q- or normal)\n> 1 lineage cytopenia\n\nChronic myelogenous leukemia (CML)\n\nDisease progression\nAccelerated phase\nBlast crisis (myeloid or lymphoid)\n\nFollicular lymphoma\n\nPoor response to initial treatment\nAfter second or subsequent relapse\nTransformation to diffuse large B-cell lymphoma\n\nAggressive T-cell or B-Cell lymphoma\n\nAfter second or subsequent relapse\nNo CR with initial treatment\nMantle Cell: After second or subsequent relapse\n\nHodgkin's lymphoma\n\nNo initial CR\nAfter second or subsequent relapse\nMultiple myeloma: Patients failing autologous transplantation with chromosome 13 abnormalities, first response lasting less than 6 months, or Î²-2 microglobulin > 3 mg/L may be considered for this protocol after initial therapy.\n\nExclusion Criteria:\n\nInadequate Organ Function as defined by:\n\nRenal: Creatinine clearance > 60ml/min\nHepatic: Bilirubin, AST/ALT < 2x upper limit of normal\nPulmonary function: DLCOcorr > 50% normal\nCardiac: left ventricular ejection fraction > 45%\nKarnofsky score (adults) < 70% or Lansky score < 50% (pediatrics)",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "12 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "William YK Hwang, MBBS, FRCP",
            "OverallOfficialAffiliation": "Singapore General Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Singapore General Hospital",
            "LocationCity": "Singapore",
            "LocationZip": "169608",
            "LocationCountry": "Singapore"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007938",
            "ConditionMeshTerm": "Leukemia"
          },
          {
            "ConditionMeshId": "D000009190",
            "ConditionMeshTerm": "Myelodysplastic Syndromes"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000001855",
            "ConditionAncestorTerm": "Bone Marrow Diseases"
          },
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10372",
            "ConditionBrowseLeafName": "Lymphoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15507",
            "ConditionBrowseLeafName": "Syndrome",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11210",
            "ConditionBrowseLeafName": "Multiple Myeloma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M26741",
            "ConditionBrowseLeafName": "Neoplasms, Plasma Cell",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10097",
            "ConditionBrowseLeafName": "Leukemia",
            "ConditionBrowseLeafAsFound": "Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11297",
            "ConditionBrowseLeafName": "Myelodysplastic Syndromes",
            "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M13316",
            "ConditionBrowseLeafName": "Preleukemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4286",
            "ConditionBrowseLeafName": "Bone Marrow Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3543",
            "ConditionBrowseLeafName": "Lymphosarcoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3947",
            "ConditionBrowseLeafName": "Multiple Myeloma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3993",
            "ConditionBrowseLeafName": "Myelodysplastic Syndromes",
            "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M247314",
            "InterventionBrowseLeafName": "Flt3 ligand protein",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}